WASHINGTON — The Trump administration filled four senior positions at the Food and Drug Administration on Tuesday, following its nomination of Heidi Overton to lead the agency late last month.
The administration said three officials who have been acting will now assume the roles permanently. Michael Davis, a psychiatrist, will become director of the Center for Drug Evaluation and Research; Karim Mikhail, a former Merck executive, will lead the Center for Biologics Evaluation and Research; and Bret Koplow, an attorney who has served at the FDA since 2011, will direct the Center for Tobacco Products.
Jared Seehafer will be the FDA’s first deputy commissioner for technology and artificial intelligence. He joined the agency as an adviser in 2025, bringing experience as a life‑science software founder and biotech investment adviser. Under the Trump administration, the FDA has encouraged staff to adopt AI tools to accelerate review processes.
Also Read
- Google Gemini Lawsuit Tests AI Safety Limits as Schools and Researchers Weigh New Responses
- Assessing and Managing HIV’s Higher Heart Disease Risks
- Caffeinated Energy Drinks Linked to Elevated Cardiac Arrest Reports
- STAT+: Doctors on Kennedy’s influential preventive care panel have major conflicts of interest, filings reveal
